title: Virus-like particle vaccine protects against H3N2 canine influenza virus in dog.
abstract: In the present study, virus-like particles (VLPs) were evaluated as a candidate veterinary vaccine against canine influenza virus (CIV) subtype H3N2. Specific pathogen-free (SPF) beagle dogs received a single injection of a VLP vaccine containing hemagglutinin (HA) and M1 protein of CIV H3N2 (H3 HA VLP). The vaccine was tested at 3 different doses with an adjuvant and 1 dose without an adjuvant. To evaluate the immunogenicity and protective efficacy of the H3 HA VLP vaccine, we performed hemagglutination inhibition tests to determine serological immune responses and conducted challenge studies using SPF beagle dogs. The addition of Montanide ISA 25 adjuvant significantly increased the immunogenicity of the H3 HA VLP vaccine. The experimental infection study showed that a single dose of H3 HA VLP vaccine induced protection against wild-type virus challenge in dogs. These results provide support for continued development of the VLP as an animal vaccine against influenza virus.
authors.affiliation: Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea.
authors.forename: Dong-Hun
authors.initials: DH
authors.lastname: Lee
authors.forename: Sang-Woo
authors.initials: SW
authors.lastname: Bae
authors.forename: Jae-Keun
authors.initials: JK
authors.lastname: Park
authors.forename: Jung-Hoon
authors.initials: JH
authors.lastname: Kwon
authors.forename: Seong-Su
authors.initials: SS
authors.lastname: Yuk
authors.forename: Jae-Min
authors.initials: JM
authors.lastname: Song
authors.forename: Sang-Moo
authors.initials: SM
authors.lastname: Kang
authors.forename: Yong-Kuk
authors.initials: YK
authors.lastname: Kwon
authors.forename: Hwi-Yool
authors.initials: HY
authors.lastname: Kim
authors.forename: Chang-Seon
authors.initials: CS
authors.lastname: Song
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D016367:Baculoviridae; D004285:Dogs; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000662:veterinary*; D058425:Vaccines, Virus-Like Particle / Q000627:therapeutic use*; D014763:Viral Matrix Proteins / Q000276:immunology; D017201:Virus Shedding
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; D058425:Vaccines, Virus-Like Particle; D014763:Viral Matrix Proteins; C483468:hemagglutinin, human influenza A virus